However, anti-angiogenic agents have not been as successful as initially imagined in HCC, mainly because tumors that typically responded initially to anti-VEGF therapies quickly become resistant.10, 11, 12, 13 However, transarterial embolization (TAE) and transarterial chemoembolization (TACE) have become the major interventional treatments for HCC patients. This evidence concerns the gene VEGFA and hepatocellular carcinoma.